United Therapeutics Corporation (UTHR): Price and Financial Metrics


United Therapeutics Corporation (UTHR): $218.95

8.81 (+4.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add UTHR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

UTHR POWR Grades


  • UTHR scores best on the Value dimension, with a Value rank ahead of 96.41% of US stocks.
  • UTHR's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • UTHR's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

UTHR Stock Summary

  • UTHR has a higher market value than 78.55% of US stocks; more precisely, its current market capitalization is $8,054,274,923.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.32 for UNITED THERAPEUTICS Corp; that's greater than it is for only 18.4% of US stocks.
  • The volatility of UNITED THERAPEUTICS Corp's share price is greater than that of only 17.88% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to UNITED THERAPEUTICS Corp, a group of peers worth examining would be TTNP, DYAI, ENTX, SDGR, and PSNL.
  • UTHR's SEC filings can be seen here. And to visit UNITED THERAPEUTICS Corp's official web site, go to www.unither.com.

UTHR Valuation Summary

  • In comparison to the median Healthcare stock, UTHR's price/earnings ratio is 43.84% lower, now standing at 20.5.
  • Over the past 243 months, UTHR's price/sales ratio has gone down 62.8.
  • UTHR's price/earnings ratio has moved up 25.2 over the prior 243 months.

Below are key valuation metrics over time for UTHR.

Stock Date P/S P/B P/E EV/EBIT
UTHR 2021-08-31 6.1 2.7 20.5 15.8
UTHR 2021-08-30 6.0 2.6 20.2 15.5
UTHR 2021-08-27 6.0 2.6 20.1 15.5
UTHR 2021-08-26 5.8 2.5 19.6 15.1
UTHR 2021-08-25 5.8 2.5 19.6 15.1
UTHR 2021-08-24 5.8 2.5 19.6 15.1

UTHR Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 3.35%.
  • Its 4 year revenue growth rate is now at -4.3%.
  • The 2 year revenue growth rate now stands at -17.29%.
Over the past 15 months, UTHR's revenue has gone up $276,000,000.

The table below shows UTHR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1,685.5 598.2 475.8
2021-09-30 1,655.2 549.8 462.4
2021-06-30 1,590.6 615.1 470.9
2021-03-31 1,506.1 630.9 405.4
2020-12-31 1,483.3 755.7 514.8
2020-09-30 1,409.5 732 468.6

UTHR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • UTHR has a Quality Grade of A, ranking ahead of 95.85% of graded US stocks.
  • UTHR's asset turnover comes in at 0.344 -- ranking 133rd of 681 Pharmaceutical Products stocks.
  • NEOG, AMGN, and AERI are the stocks whose asset turnover ratios are most correlated with UTHR.

The table below shows UTHR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.344 0.925 0.142
2021-03-31 0.337 0.928 0.126
2020-12-31 0.344 0.927 0.167
2020-09-30 0.340 0.928 0.165
2020-06-30 0.354 0.922 0.158
2020-03-31 0.364 0.922 0.199

UTHR Price Target

For more insight on analysts targets of UTHR, see our UTHR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $231.89 Average Broker Recommendation 1.35 (Strong Buy)

UTHR Stock Price Chart Interactive Chart >

Price chart for UTHR

UTHR Price/Volume Stats

Current price $218.95 52-week high $220.02
Prev. close $210.14 52-week low $158.38
Day low $209.12 Volume 996,000
Day high $220.02 Avg. volume 461,525
50-day MA $184.38 Dividend yield N/A
200-day MA $194.01 Market Cap 9.92B

United Therapeutics Corporation (UTHR) Company Bio


United Therapeutics develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension. The company was founded in 1996 and is based in Silver Spring, Maryland.


UTHR Latest News Stream


Event/Time News Detail
Loading, please wait...

UTHR Latest Social Stream


Loading social stream, please wait...

View Full UTHR Social Stream

Latest UTHR News From Around the Web

Below are the latest news stories about UNITED THERAPEUTICS Corp that investors may wish to consider to help them evaluate UTHR as an investment opportunity.

United Therapeutics (UTHR) Misses Q4 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 24, 2022--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2021. Full year total revenues rose to $1,686 million, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2021.

Yahoo | February 24, 2022

United Therapeutics Q4 2021 Earnings Preview

United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is $4.05 (+22.4% Y/Y) and the consensus Revenue Estimate is $427.59M (+11.1% Y/Y). Over the last 2 years, UTHR has beaten EPS estimates 75% of the time and has...

Seeking Alpha | February 23, 2022

Is United Therapeutics (UTHR) Stock a Suitable Value Pick Now?

Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Yahoo | February 21, 2022

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2021 Financial Results Before the Market Opens on Thursday, February 24, 2022

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 21, 2022--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before the market opens on Thursday, February 24, 2022.

Yahoo | February 21, 2022

Read More 'UTHR' Stories Here

UTHR Price Returns

1-mo 17.56%
3-mo 30.55%
6-mo 13.07%
1-year 18.18%
3-year 150.23%
5-year 83.87%
YTD 1.33%
2021 42.35%
2020 72.33%
2019 -19.12%
2018 -26.39%
2017 3.15%

Continue Researching UTHR

Want to see what other sources are saying about UNITED THERAPEUTICS Corp's financials and stock price? Try the links below:

UNITED THERAPEUTICS Corp (UTHR) Stock Price | Nasdaq
UNITED THERAPEUTICS Corp (UTHR) Stock Quote, History and News - Yahoo Finance
UNITED THERAPEUTICS Corp (UTHR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6097 seconds.